Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03111121 · ClinicalTrials.gov registry record · Phase 4
Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy
A Phase 4 study, sponsored by West Virginia University.
- Completed
- Registry status
- Phase 4
- Development phase
- 79
- Enrollment target
NCT03111121 is a Phase 4 study that has completed, run by West Virginia University. The registered enrollment target is 79 participants.
The verdict
NCT03111121, a Phase 4 study, has completed, sponsored by West Virginia University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 79 participants
- Enrollment target
Study Summary
Use of Muscle relaxant and reversal with Sugammadex at end of airway procedures will reduce the time to extubation after end of procedure
Interventions
- DRUG Sugammadex
- DRUG neostigmine
- DRUG glycopyrrolate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2017-05-04 |
| Est. Completion | 2019-05-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03111121
The ClinicalTrials.gov registry entry for NCT03111121 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is West Virginia University, which has 122 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sugammadex is the first listed.
NCT03111121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03111121 about?
NCT03111121 is a clinical study titled "Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy". Use of Muscle relaxant and reversal with Sugammadex at end of airway procedures will reduce the time to extubation after end of procedure
What is the current status of trial NCT03111121?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 79 participants. The study started on 2017-05-04. Estimated completion is 2019-05-30.
What interventions are being tested in trial NCT03111121?
The interventions under investigation include: Sugammadex (DRUG), neostigmine (DRUG), glycopyrrolate (DRUG).
Who is sponsoring clinical trial NCT03111121?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.